Expands LATAM Footprint First Supply Agreement Costa Rica
| Stock | Bioxyne Ltd (BXN.ASX) |
|---|---|
| Release Time | 11 May 2026, 8:24 a.m. |
| Price Sensitive | Yes |
Bioxyne Expands LATAM Footprint with First Supply Agreement in Costa Rica
- Bioxyne executes expanded supply agreement with Remidose LATAM to supply Dr Watson® cannabis flower to Costa Rica
- Represents first international supply of medicinal cannabis flower to Costa Rica's regulated market
- Initial shipment to exceed $500,000, with repeat orders expected
Bioxyne Ltd, through its wholly owned subsidiary Breathe Life Sciences (BLS), has executed an expanded supply agreement with Remidose LATAM SRL to include the supply of three Dr Watson® cannabis flower SKUs to Costa Rica. This agreement represents the first international supply of medicinal cannabis flower into Costa Rica's regulated market. The expansion of the initial December 2025 agreement to include cannabis flower highlights strong early-stage demand and reinforces the strategic alignment between Bioxyne and Remidose. The expanded agreement builds on the existing relationship between BLS and Remidose, under which BLS will supply cannabis pastilles for distribution into Costa Rica and Panama, further strengthening Bioxyne's presence across LATAM markets. Product registration for Costa Rica is well advanced, and initial shipments of Dr Watson® cannabis flower are expected prior to 30 June 2026, with the first shipment to exceed $500,000. Based on current demand forecasts, the Company expects repeat orders, subject to market conditions and regulatory approvals. This expansion establishes early Dr Watson® brand positioning and creates a regulatory and distribution foothold intended to support broader expansion across LATAM, as Bioxyne leverages its established export capability and regulatory experience to enter the market at an early stage of development.
Initial shipment of Dr Watson® cannabis flower to Costa Rica expected to exceed $500,000 prior to 30 June 2026. The Company expects repeat orders, subject to market conditions and regulatory approvals.
Bioxyne's entry as the first international supplier of medicinal cannabis flower (soon to be followed by pastilles) into the Costa Rican market establishes a regulatory and distribution foothold intended to support broader expansion across LATAM as the markets continue to open.